Last reviewed · How we verify
NCT05021926
Safety and Performance of DKL Crosslinked Sodium Hyaluronate 26 Dermal Filler for Cheek Augmentation
NA trial testing DKL crosslinked sodium hyaluronate 26 in Aging Problems in 48 participants. Completed in 6 January 2023.
6 January 2023
Quick facts
| Lead sponsor | Dr. Korman Laboratories Ltd. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 48 |
| Start date | 30 August 2021 |
| Primary completion | 6 January 2023 |
| Estimated completion | 6 January 2023 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- DKL crosslinked sodium hyaluronate 26
- Juvéderm Voluma™ with lidocaine (Allergan, Inc)
Conditions studied
- Aging Problems — all drugs for Aging Problems →
Sponsor
Dr. Korman Laboratories Ltd.
Who can join
Adults 18 to 65, any sex, with Aging Problems. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a pivotal, prospective, active-controlled, randomized, double blinded (blinded evaluator and subject), intra-individual split-face comparison, non-inferiority study of DKL crosslinked sodium hyaluronate 26 versus Juvederm Voluma™ after treatment of subcutaneous to upper-periostea tissue, or deep dermis implantation for cheek augmentation and age-related facial-volume deficit.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05021926
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Aging Problems
Currently open trials in the same condition.
- NCT07144293 — Improving Physical Ability and Cellular Senescence Elimination in HIV · Phase 2 · active not recruiting
- NCT06511297 — Metabolic Control of Aging and Disease - the MetAGE Deep Phenotyping Cohort · recruiting
- NCT06175871 — New Clinical Rehabilitation Approach for the Management of Falls Risks · NA · recruiting
- NCT06448052 — Umbilical Cord Mesenchymal Stem Cell for Aging-related Low-grade Inflammation · Phase 1, PHASE2 · active not recruiting
- NCT06124339 — Brain Health Virtual Reality Study · NA · recruiting
Other Dr. Korman Laboratories Ltd. trials
Trials by the same sponsor.
- NCT05021913 — Safety and Performance of DKL Crosslinked Sodium Hyaluronate 23 Dermal Filler for Improvement of NLF Appearance · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05021926 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dr. Korman Laboratories Ltd.
- Last refreshed: 5 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05021926.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing